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Abstract
Background: Endothelial progenitor cell (EPC) participates in endothelial repair and new blood vessel growth. Cardiovascular 
pharmacotherapy has been shown to improve the amount and function of EPC in patients with cardiovascular risk. Many studies report 
that statins have a beneficial effect on EPC by increasing the number and function of EPC, including the migration function. Therefore, 
we conducted a study to analyze the effects of three different statins on EPC migration. Our aim is to analyze the effect of statins on EPC 
migration from peripheral blood of stable coronary artery disease (SCAD) patient.
Methods: This was an in vitro true experimental post-test only control group design. The MNCs were isolated from peripheral 
blood of SCAD patient and were cultured in Stemline II Hematopoietic Stemcell Expansion Medium in 3 days. Then samples were put 
into four groups, simvastatin 0.5 µmol/L, atorvastatin 0.5 µmol/L, rosuvastatin 0.5 µmol/L and control, then incubated for 48 hours. 
Immunocytochemical examination was performed to evaluate expression of CD34+. On the 5th day of culture,  5x105 cells per group 
were transferred to the upper chamber of the transwell system, then incubated for 1 day. Cells that migrated to the lower chamber of 
transwell system were calculated by automatic cell counter with typhan blue coloring. Data were analyzed by independent T-test and 
ANOVA. 
Results: The results of independent T-tests showed a significant increase in EPC migration in the simvastatin, atorvastatin, and 
rosuvastatin groups compared with the control group (234000 ± 1290.994, 265000 ± 1290.994, 203000 ± 1290. 994 vs 174071.43 
± 1426 785, p <0.05). EPC migration also differed between statin groups, where the highest effect was found in the atorvastatin 
group. EPC migration in the atorvastatin group was higher than the simvastatin group (265,000 ± 1290,994 vs 234,000 ± 1290,994, p 
<0.05), and simvastatin was higher than the rosuvastatin (234,000 ± 1290,994 vs 203000 ± 1290. 994, p < 0.05). Immunocytochemical 
examination showed a positive expression on CD34+.
Conclusion: Statins increase EPC migration from peripheral blood of SCAD patient. Atorvastatin showed the highest EPC migration, 
followed by simvastatin, and rosuvastatin.
(Indonesian J Cardiol. 2019;40:202-205)
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Introduction
Coronary heart disease is a major cause of morbidity and mortality worldwide. Improvements in the quality of therapy for this disease were not accompanied by a 
significant reduction in recurrence rates. The discovery 
that cells originating from the bone marrow known 
as endothelial progenitor cells (EPC) play a role in 
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endothelial cell repair and new vascular growth has 
changed the model of the pathogenesis of cardiovascular 
disease1. EPC is part of a single nucleated cell or 
mononuclear cell (MNC) that has several hematopoetic 
stem cell markers, namely CD34 and CD133. Some 
physiological stimuli, ischaemic response, and some 
drugs have been known affecting the number and 
function of EPC2. Statins or HMG-CoA reductase 
inhibitors reduce cholesterol levels through inhibition 
of HMG-CoA reductase. Some studies report statins 
to have beneficial effects on EPC by increasing EPC 
proliferation and migration through activation of the 
endothelial nitric oxide synthase (eNOS) pathway3. 
In a previous study, it was found that simvastatin, 
atorvastatin, and rosuvastatin provided an increase of 
EPC proliferation in peripheral blood of SCAD patients 
when compared with controls, where atorvastatin 
showed the most significant proliferation result4.
Methods
Blood samples were taken from patients with SCAD 
which were men, 40-59 years old, had narrowing of 
≥50% in the left main coronary artery and ≥70% 
in one or several of the major coronary arteries from 
angiography. 
 Patients with history of acute myocardial infarction, 
acute limb ischemia, stent placement, coronary artery 
bypass grafting, diabetes mellitus, smoking, and anemia 
were excluded. 
 Written informed consent was obtained from 
patients before peripheral blood drawing. The protocol 
was approved by local ethics committee (0379/KEPK/
VII/2018). 
Isolation and culture of EPCs 
Forty ml of peripheral blood from SCAD patient 
was diluted with phosphate buffered saline (PBS) 
containing 2% of fetal bovine serum (FBS). It was then 
centrifuged on Ficoll-Histopaque density gradients and 
interface mononuclear cells (MNCs) were collected. 
After two washes in PBS containing 2% of FBS, pellet 
were diluted with stemline II hematopoietic stemcell 
expansion medium, and these cells were counted using 
hemocytometry. 5x106cells/ml mononuclear cells 
were plated on 6-fibronectin coated well plates. After 
two days, nonadherent cells were transferred into new 
fibronectin coated well plates and incubated again for 
24 hours.
Statin 
After 3 days, EPC culture was divided into 4 groups. Each 
group was given simvastatin 0.5μmol/L, atorvastatin 
0.5μmol/L, rosuvastatin 0.5μmol/L, and control, then 
cell culture was incubated for next 48 hours
EPC migration assay 
After EPC culture was incubated for 72 hours, 5 x 
105 cells / ml were transferred to the transwell upper 
chamber. The bottom chamber transwell was given 2 
ml of media. After 24 hours of incubation, the non-
migratory cells on the upper side of upper transwell insert 
were manually removed using sterile cotton swabs. The 
upper and lower side of insert system were washed using 
PBS. Cells on the bottom side of transwell insert system 
were detached by trypsination method (Figure 1). The 
new medium was placed on the receiver plate and added 
500μl of trypsin + EDTA solution 0.5%, then the insert 
was returned to the receiver plate and incubated for 10 
minutes. The detached cells on the receiver plate were 
read using a cell counter with tryphan blue coloring to 
determine the number of migrating cells.
Figure 1. Migrated EPC Cells. A: EPC cells in bottom side 
of insert transwell of Simvastatin 0.5 µmol / L group, B: 
EPC cells in bottom side of insert transwell of Atorvastatin 
0.5 µmol / L group, C: EPC cells in bottom side of insert 
transwell of Rosuvastatin 0.5 µmol / L group, D: EPC cells in 
bottom side of insert transwell of control group
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Immunofluorescence assay 
Cells were washed with PBS and fixed with 3% 
formaldehyde for 15 minutes. Cells then added with 
1% serum and washed again with PBS. Cells were 
stained with a FITC anti-CD34 antibody. Expression of 
the cells was documented with fluorescence microscope
Statistical analysis 
Data were expressed as mean±SD. To analyse differences, 
one-way ANOVA was used. Differences were considered 
significant if p-values were <0.05. All statistical analyses 
were performed with SPSS for Windows (IBM Corp., 
Armonk, NY). 
Results 
Statin increases EPC migration
To investigate the effect of statins on EPC migration, we 
added three different types of statins on EPC cultures. 
In this study showed a significant increase of EPC 
migration in simvastatin, atorvastatin, and rosuvastatin 
groups compared with control group (234000 ± 1290. 
994, 265000 ± 1290. 994, 203000 ± 1290. 994 vs. 
174071.43 ± 1426. 785, p<0.05). It also revealed 
significant difference in EPC migration between each 
experiment groups, which atorvastatin showed the 
highest effect. EPC migration in atorvastatin was higher 
than simvastatin group (265000 ± 1290vs. 234000 ± 
1290. 994, p<0.05), and simvastatin gruop was also 
higher than rosuvastatin group (234000 ± 1290. 994 vs. 
203000 ± 1290. 994, p<0.05) (Figure 2). 
Figure 2. Statins increase EPC migration. EPC migration 
were expressed as cell/ml.
Immunofluorescence assay 
CD34 is one of the positive marker for EPC. Before 
migration assay, one of the well was washed with 
PBS and stained with a FITC anti-CD34 antibody. 
Expression of CD34 was green under fluorescence 
microscope (Figure3). 
Figure 3. Immunofluorescence expression of CD34
Discussion
The results of the this study demonstrated that statin 
significantly increased EPC migration in patients with 
SCAD. There were different level in EPC migration 
induced by each statins. Atorvastatin had the highest 
effect of EPC migration, and simvastatin could promote 
EPC migration more than rosuvastatin. 
 Many studies have reported the beneficial effects of 
statin on EPCs. Similar to this result, Llevadot, et al. 
reported that simvastatin increased EPC proliferative 
activity and function of EPC using EPC culture assay 
of peripheral blood from simvastatin-treated animals 
in vivo5. Spiel, et al. explored the effect of statin using 
simvastatin and rosuvastatin. The results showed that five 
days pre-treatment with 80 mg of simvastatin increased 
CFU 3.5-fold, whereas pre-treatment with 40 mg of 
rosuvastatin led to a 2.6 fold increase as compared to 
baseline values6. Dimmeler, et al. also used three different 
types of statins, which were simvastatin, mevastatin, and 
atorvastatin. The results demonstrated that incubation 
of isolated human MNCs with statin increased the 
number of EPCs. Atorvastatin augmented the number 
and function of EPCs more than simvastatin7. 
 Dimmeler, et al. demonstrated that statins enhanced 
the mobilization of EPCs from bone marrow to newly 
forming blood vessels through the PI3K/Akt pathway, 
which lead to an increase in endothelial nitric oxide 
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synthase (eNOS) and nitric oxide (NO) production, as 
NO is essential for EPC proliferation7,8. The mechanism 
underlying different effect of statins on EPC migration 
still needs to be determined. Although all statins share 
a common mechanism of action, they differ in terms 
of their chemical structures, pharmacokinetic profiles, 
and lipid modifying efficacy. These differences might 
influence the effect on EPC migration induced by 
different types of statin. 
Conclusion
The results of this study define that statin increases EPC 
migration from peripheral blood of SCAD patient. 
Our data suggests that atorvastatin has the highest 
EPC migration effect, followed by simvastatin, and 
rosuvastatin. 
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